Company Description
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States.
It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.
The company’s lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.
It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase I/Ib clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations.
The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; Foundation Medicine, Inc. for the provision of prospective genomic profiling of lunresertib alone or in combinations in genomically-defined patient populations; cooperative research and development agreement with US National Cancer Institute to advance the development of Camonsertib; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer.
Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montreal, Canada.
| Country | Canada |
| Founded | 2016 |
| IPO Date | Jun 19, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 179 |
| CEO | Lloyd Segal |
Contact Details
Address: 7171 Frederick-Banting, Building 2, Suite 270 Montreal, QC H4S 1Z9 Canada | |
| Phone | 857 412 7018 |
| Website | reparerx.com |
Stock Details
| Ticker Symbol | RPTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001808158 |
| CUSIP Number | 760273102 |
| ISIN Number | US7602731025 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Lloyd Mitchell Segal | President, Chief Executive Officer and Director |
| Dr. Maria Koehler M.D., Ph.D. | Executive Vice President and Chief Medical Officer |
| Dr. Daniel Durocher Ph.D. | Co-Founder |
| Dr. Frank Sicheri Ph.D. | Co-Founder |
| Dr. Agnel Sfeir Ph.D. | Co-Founder |
| Dr. Michael Zinda Ph.D. | Executive Vice President and Chief Scientific Officer |
| Daniel Belanger | Executive Vice President of Human Resource |
| Cameron Black Ph.D. | Executive Vice President of Discovery |
| Philip Herman | Executive Vice President, Chief Commercial and Portfolio Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 424B5 | Filing |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Aug 28, 2024 | 8-K | Current Report |
| Aug 19, 2024 | EFFECT | Notice of Effectiveness |
| Aug 8, 2024 | UPLOAD | Filing |
| Aug 7, 2024 | 8-K | Current Report |